Ruel Marc, Song Jianming, Sellke Frank W
University of Ottawa, Ottawa, Ontario, Canada.
Mol Cell Biochem. 2004 Sep;264(1-2):119-31. doi: 10.1023/b:mcbi.0000044381.01098.03.
Therapeutic angiogenesis aims at restoring perfusion to chronically ischemic myocardial territories by using growth factors or cells, without intervening on the epicardial coronary arteries. Despite angiogenesis having received considerable scientific attention over the last decade, it has not yet been shown to provide clinical benefit and is still reserved for patients who have failed conventional therapies. Nevertheless, angiogenesis is a very potent physiologic process involved in the growth and development of every animal and human, and it is likely that its use for therapeutic purposes, once its underlying mechanistic basis is better understood, will one day become an important modality for patients with CAD and other types of organ ischemia. This review summarizes current knowledge in therapeutic angiogenesis research.
治疗性血管生成旨在通过使用生长因子或细胞来恢复慢性缺血心肌区域的灌注,而无需干预心外膜冠状动脉。尽管在过去十年中血管生成受到了相当多的科学关注,但尚未证明它能带来临床益处,目前仍仅适用于常规治疗失败的患者。然而,血管生成是每个动物和人类生长发育过程中非常重要的生理过程,一旦其潜在的机制基础得到更好的理解,其用于治疗目的很可能有朝一日成为冠心病和其他类型器官缺血患者的重要治疗方式。本综述总结了治疗性血管生成研究的当前知识。